Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma

Fig. 1

Percentage change from baseline in the sum of index lesions in the liver. Waterfall plot of percentage change from baseline in the sum of index lesions in the liver, with pancreatic lesion response, CA19-9 response and tumour characteristics. § Patients switching protocol chemotherapy to gemcitabine 2.1–8.1 months after the start of 5FU (red asterisk); Tumour response by RECIST v1.0 (change while on 5FU in blue; change while on gemcitabine in red); nm: non-measurable disease; baseline value < ULN (excluded from analysis of mean change in CA19-9)

Back to article page